HaCaT human keratinocytes (American Type Culture Collection, Boulecard Manassas, VA, USA) were cultured in Dulbecco's modified Eagle medium (Gibco/Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin/streptomycin (Gibco/Life Technologies) at 37℃ in an atmosphere of 5% CO₂. Kinetin was purchased from Sigma-Aldrich and dissolved in dimethyl sulfoxide.

HaCaT cells were seeded at a density of 3×10³ cells in 96-well plates and incubated for 24 h. The cells were then incubated with kinetin (0~600 µM) for 24 h. HaCaT cell toxicity due to kinetin was evaluated using a water-soluble tetrazolium salt (WST)-1 assay (EZ-Cytox Cell Viability Assay Kit; Itsbio, Seoul, Korea). WST-1 solution was added to cultured cells at a volume equal to 10% that of the culture medium, and then the cells were incubated at 37℃ for 1 h. Cell viability was evaluated by measuring the absorbance at 450 nm using an iMark microplate reader (Bio-Rad, Hercules, CA, USA).

Total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. The purity and concentration of the RNA were evaluated using a MaestroNano®, a microvolume spectrophotometer (Maestrogen, Las Vegas, NV, USA). The recommended parameters of RNA quality for cDNA synthesis were OD 260/230 >1.8 and an OD 260/280 ratio within the range of 1.8~2.0. cDNAs were synthesized using the miScript II RT Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. To evaluate the expression of INV (forward primer: 5′-GGGTGGTTATTTATGTTTGGGTGG-3′, reverse primer: 5′-GCCAGGTCCAAGACATTCAAC-3′) and KRT1 (forward primer: 5′-ATTTCTGAGCTGAATCGTGTGATC-3′, reverse primer: 5′-CTTGGCATCCTTGAGGGCATT-3′), quantitative real-time polymerase chain reaction was performed using EvaGreen dye (Solis BioDyne, Tartu, Estonia) with Line-Gene K software (Bioer Technology Co., Ltd., Hangzhou, China). The C_T value for each gene was normalized to β-actin (forward primer: 5′-GGATTCCTATGTGGGCGACGA-3′, reverse primer: 5′-CGCTCGGTGAGGATCTTCATG-3′). Relative expression levels of each gene were calculated using the 2^−ΔΔC_t method22.

The study protocols were approved by the Institutional Review Board of KISCS Incorporated (Cheongju, Korea) (IRB no. 1-70005239-A-N-01-2013-KISCS-ACA001-KSH). All subjects were informed about the objective of the study and provided informed consent and agreed to use products for skin care during the study. Forty women greater than 40 years of age were enrolled in a randomized, double-blind clinical trial (control group: 46.80±4.83 years, experiment group: 46.70±0.83 years). The subjects were selected based on age, the absence of skin conditions other than age-related conditions, and were not pregnant or nursing. All subjects were informed about the objective of the study, provided signed informed consent, and agreed to use only products for skin care during the study. Reasons for dropping out were itching, erythema, or excessive drinking or smoking. Subjects were divided into control and experimental groups consisting of 20 subjects each. All conditions were identical, other than the exposure of the experimental group to the test material. The study lasted four weeks, except no drop out. Clinical parameters were evaluated three times, namely, before application, and after 2 and 4 weeks of use. The investigator asked subjects about the condition of their skin and performed a visual examination of their skin condition, such as erythema, itching, scale, edema, tingling, and burning sensation, at every visit. The cream was prepared by incorporating the ingredients in the three phases (A, B, C). Ingredients in the A phase (distilled water, glycerin, 1,3-butylene glycol) were combined and heated until all the components were melted, and ingredients in the B phase (distilled water, dipotassium phosphate, sodium hydroxylate, kinetin) were combined and heated to the same temperature, to ensure homogeneity. The A and B phases were combined and emulsified using a homo mixer (Tokushu Kika Kogyo Co., Ltd., Osaka, Japan) at 5,000 rpm for 10 min. The mixture was cooled to 60℃ and blended with the homogenized phase C (emulium delta, sepipuls 400) at 5,000 rpm for 10 min. By then, the temperature of the mixture had dropped to 45℃. The mixture was combined and homogenized, while maintaining the pH at 6.2. The cream provided to the experimental group contained 2% (wt%) kinetin and the cream provided to the control group was prepared using the same volume of water in place of kinetin.

To investigate the improvement in skin barrier function, subjects were instructed to apply 2 g of test material to the face every morning and night for 4 weeks. Subjects and investigators were blinded to test and control treatments. Moisture and transepidermal water loss (TEWL) were measured on the right cheek and skin texture was evaluated on the left side of the forehead. At every visit, before measurements were taken, all subjects washed with the cleanser provided and lay quietly in a room with constant temperature (22℃±1℃) and humidity (45%±5%) so that all subjects would be evaluated under the same conditions.

To evaluate improvement in skin moisture, the DermaLab USB moisture probe (Cortex Technology Inc., Hadsund, Denmark) was applied and data were analyzed using the associated application software version 1.09. All subjects were measured on the same region of the right cheek five consecutive times, and the mean, maximum, and minimum values were determined. Measurements were taken three times, namely, before application, and after 2 and 4 weeks of use. The device applies the conductance measurement principle to measure the water-binding capacity of the stratum corneum (SC). This value correlates with skin moisture and is expressed in microsiemens (µS).

To evaluate improvement in TEWL, the DermaLab USB TEWL probe (Cortex Technology Inc.) was applied and data were analyzed using the associated application software version 1.09. Five consecutive measurements were taken on the subject's right cheek, and the mean, maximum, and minimum values were determined. Measurements were taken three times, namely, before application and at 2 and 4 weeks after the application.

Facial skin evenness measured by PRIMOS Lite (field of view 45×30; GFMesstechnik GmbH, Teltow, Germany) was used to obtain clinical images. Captured images were analyzed using the associated imaging software, PRIMOS Lite version 5.6E. Three consecutive clinical images of the left side of the subject's forehead were captured. Facial skin roughness was assessed based on the Ra value, which is the average of all heights and depths relative to the reference plane. Measurements were taken three times, namely, before application, and at 2 and 4 weeks after the application. The Ra value is the most widely used parameter of facial skin roughness and is the arithmetic mean of the maximum values of all measurements.

In cellular efficacy tests, all results are presented as the mean percentage±standard deviation of three independent experiments. Differences with a p-value of less than 0.05 or 0.001, as determined by Student's t-test, were considered statistically significant. In clinical efficacy tests, statistical analyses were conducted using SPSS software (PASW Statistics ver. 17.0 for Windows; IBM Co., Armonk, NY, USA). Paired t-tests were performed in cases of repeated measurements on the same subject. In clinical test, all statically analysis was compared between 0 week and 2 or 4 weeks using paired t-test which analyze statically significant by a comparison of experimental measured value of each entity in 0 weeks and 2 or 4 weeks. To analyze subject questionnaires, the mean values, standard deviation, and percentage were used. The formula used to measure the percent change for each skin parameter was

where A is defined as the individual value of any parameter at the 2 and 4 week visits and B represents the zero hour of the assessed parameter.

To determine whether kinetin affects HaCaT cell viability, cells were exposed to kinetin at concentrations ranging from 0~600 µM for 24 h. As shown in Fig. 1, kinetin reduced cell viability by 8.88% at 200 µM, 18.99% at 400 µM, and 29.78% at 600 µM. Kinetin-induced cytotoxicity increased significantly at concentrations greater than 200 µM. Thus, we used 200 µM as the maximum concentration in subsequent experiments.

Expression of involucrin, a marker of keratinocyte differentiation, was not altered by the treatment of HaCaT cells with 0.25 mM CaCl₂. But when cells were treated with kinetin, involucrin mRNA increased in a dose-dependent manner. The addition of kinetin following treatment with 0.25 mM CaCl₂ increased the level of involucrin mRNA to that of cells treated with 2 mM CaCl₂ alone (Fig. 2). Simultaneously, we investigated the gene expression of another keratinocyte differentiation maker, keratin 1. As seen for involucrin, keratin 1 expression was not altered by treatment of HaCaT cells with 0.25 mM CaCl₂. However, when these cells were treated with kinetin, keratin 1 expression increased markedly (Fig. 3).

Keratinocyte moisture content is pivotal for maintaining moisture in the skin. Normal keratinocytes maintain 10%~30% moisture; however, when moisture content drops below 10%, keratinocytes are unable to maintain the skin's barrier function as skin becomes dry, acquires an uneven texture, and produces wrinkles, which accelerate senescence23. In this study, to evaluate the efficacy of kinetin treatment on skin, we investigated the improvement in skin moisture after the treatment with a kinetin-containing cream.

We analyzed skin moisture content using the DermaLab USB moisture probe. Our data demonstrate that the moisture content of the control group, which used the non-kinetin-containing cream, was 388.10 µS before use, 389.96 µS after 2 weeks, and 390.72 µS after 4 weeks of application (Fig. 4). To compare the improvement at 2 and 4 weeks, we calculated and expressed the degree of improvement (Fig. 4). Consequently, the moisture content of the control group increased by 0.48% and 0.68% after 2 and 4 weeks, respectively. These changes were not statistically significant (p>0.05), indicating that the non-kinetin-containing cream had no measurable effect on moisture content. In contrast, the moisture content in the experimental group, which used kinetin-containing cream, was 413.34 µS before use, 551.39 µS after 2 weeks, and 619.98 µS after 4 weeks (Fig. 4). Interestingly, the use of the kinetin-containing cream significantly improved skin moisture by 33.40% and 49.99% after 2 and 4 weeks, respectively (p<0.001). These experiments demonstrate that the use of the kinetin-containing cream resulted in improved skin moisture content.

Next, to determine the efficacy of kinetin as a skin moisturizer, we used the DermaLab USB TEWL probe to investigate TEWL in the skin of subjects who had used control or kinetin-containing cream. The TEWL of control subjects was 9.59 g m⁻² h⁻¹ before use, 9.48 g m⁻² h⁻¹ after 2 weeks, and 9.38 g m⁻² h⁻¹ after 4 weeks (Fig. 5). To compare the improvement at 2 and 4 weeks, we calculated the improvement as a percentage based on the value before application. Consequently, the TEWL in the control group increased by 1.15% and 2.19% after 2 and 4 weeks of use, respectively. These changes were not statistically significant (p>0.05), indicating that the non-kinetin-containing cream had no measurable effect on TEWL. In contrast, TEWL in the experimental group was 9.96 g m⁻² h⁻¹ before use, 8.92 g m⁻² h⁻¹ after 2 weeks, and 7.08 g m⁻² h⁻¹ after 4 weeks (Fig. 5). To compare the improvement at 2 and 4 weeks, we calculated the improvement in TEWL as a percentage based on the value before application. Use of the kinetin-containing cream significantly improved TEWL by 10.40% and 28.88% after 2 and 4 weeks, respectively (p<0.001). Through these experiments, we identified the improvement in TEWL as an outcome of using kinetin-containing cream.

The thickness of the SC changes depending on its moisture content. Insufficient moisture in this layer roughens skin texture gradually24. Therefore, we investigated the efficacy of kinetin-containing cream on skin texture. Facial skin evenness was measured using PRIMOS Lite. Evenness in the control group was 20.10 Ra before use, 19.95 Ra after 2 weeks, and 19.79 Ra after 4 weeks (Fig. 6). To compare the improvement at 2 and 4 weeks, we calculated the improvement as a percentage based on the value before application. Consequently, skin texture in the control group improved by 0.77% and 1.54%, after 2 and 4 weeks of use, respectively. These data were not statistically significant (p>0.05), indicating that the non-kinetin-containing cream had no measurable effect on improving skin texture. In contrast, skin evenness in the experimental group was 20.84 Ra before use, 19.30 Ra after 2 weeks, and 16.77 Ra after 4 weeks (Fig. 6). To compare the improvement after 2 and 4 weeks, we calculated the improvement as a percentage based on the value before application. Using the kinetin-containing cream significantly improved the evenness of skin texture by 7.39% and 19.54% after 2 and 4 weeks (p<0.001), respectively. Through these experiments, we revealed that use of kinetin-containing cream can improve skin texture.

In this study, investigators asked the subjects individually about the condition of their skin and performed a visual evaluation of skin reactions, such as erythema, itching, scaling, tingling, tightness, prickling, and burning sensation at every visit. No extraordinary reactions were reported based on either visual evaluation or the questionnaire.